Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation & Amortization (CF): 2012-2025

Historic Depreciation & Amortization (CF) for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $11.1 million.

  • Ptc Therapeutics' Depreciation & Amortization (CF) rose 71.28% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year decrease of 78.16%. This contributed to the annual value of $75.7 million for FY2024, which is 68.02% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Depreciation & Amortization (CF) of $11.1 million as of Q3 2025, which was up 46.50% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Depreciation & Amortization (CF) registered a high of $80.7 million during Q4 2023, and its lowest value of $6.5 million during Q3 2024.
  • For the 3-year period, Ptc Therapeutics' Depreciation & Amortization (CF) averaged around $30.7 million, with its median value being $11.1 million (2025).
  • Per our database at Business Quant, Ptc Therapeutics' Depreciation & Amortization (CF) surged by 107.65% in 2023 and then plummeted by 91.62% in 2024.
  • Ptc Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $18.8 million in 2021, then spiked by 106.61% to $38.9 million in 2022, then surged by 107.65% to $80.7 million in 2023, then slumped by 91.62% to $6.8 million in 2024, then surged by 71.28% to $11.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $11.1 million in Q3 2025, compared to $7.6 million in Q2 2025 and $7.2 million in Q1 2025.